A living evidence approach to variants of concern (VOC) and COVID-19 vaccine effectiveness

Given the continued evolution of the pandemic, updated information is crucial for guiding policy decisions and prioritizing research efforts. This living review evaluates the effectiveness of WHO-approved COVID-19 vaccines (Pfizer–BioNTech, Moderna, Oxford–AstraZeneca, and Janssen) in protecting against Long Covid outcomes caused by variants of concern in adults.

Protocol: https://www.sciencedirect.com/science/article/pii/S0264410X23010654?via%3Dihub

Infographic: https://www.ksau.ca/ve-voc-long-covid-infographic

Immunological Dashboard: https://www.ksau.ca/ve-voc-immunological-dashboard-1

Related Publications: 1. Shaver, N., Katz, M., Darko Asamoah, G., Linkins, L. A., Abdelkader, W., Beck, A., Bennett, A., Hughes, S. E., Smith, M., Begin, M., Coyle, D., Piggott, T., Kagina, B. M., Welch, V., Colijn, C., Earn, D. J. D., El Emam, K., Heffernan, J., O'Brien, S. F., Wilson, K., … Little, J. (2023). Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness. Vaccine, 41(43), 6411–6418. https://doi.org/10.1016/j.vaccine.2023.09.012

2. Beams AB, Earn DJD, Colijn C. Uncertainty in COVID-19 transmission could undermine our ability to predict long COVID. J R Soc Interface 2024;21:20240438. https://doi.org/10.1098/rsif.2024.0438.

3. Gazeau S, Deng X, Brunet-Ratnasingham E, Kaufmann DE, Larochelle C, Morel PA, et al. Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patients 2024. https://doi.org/10.1101/2024.08.01.605860.

4. Korosec CS, Wahl LM, Heffernan JM. Within-host evolution of SARS-CoV-2: how often are de novo mutations transmitted from symptomatic infections? Virus Evolution 2024;10:veae006. https://doi.org/10.1093/ve/veae006.